HIVEP3 unveiled as a therapeutic target in osteogenesis imperfecta
Sep. 16, 2024
Osteogenesis imperfecta (OI) is characterized by low bone mass, with increased risk of bone fracture due to mutations in certain genes encoding type I collagen, such as COL1A1 and COL1A2.